The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease

Scandinavian Journal of Gastroenterology

Volumn 32, Issue 11, 1997, Pages 1100-1106

  Hatlebakk, J G ^a   Johnsson, F ^b   Vilien, M ^c   Carling, L ^d   Wetterhus, S ^e   ThOgersen T ^f  

^a UNIVERSITY OF BERGEN   (Norway)

^b NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d Medical Dept   (Sweden)

^e Central Hospital   (Denmark)

^f Medical Dept   (Denmark)

Author keywords

Cisapride; Gastro oesophageal reflux disease; Maintenance therapy; Reflux symptoms

Indexed keywords

ANTACID AGENT; CIMETIDINE; CISAPRIDE; FAMOTIDINE; LANSOPRAZOLE; NIZATIDINE; NOVALUZID; OMEPRAZOLE; RANITIDINE; SUCRALFATE;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESOPHAGUS PH; FEMALE; FLATULENCE; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS;

EID: 0030776933     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529709002988     Document Type: Article

References (24)

1. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Dig Dis Sci 1976;21:953-6.
2. Howard PJ, Heading RC. Epidemiology of gastro-esophageal rellux disease. World J Surg 1992;16:288-93.
3. Berstad A, Weberg R, Frøyshov Larsen I, Hoel B, Hauer-Jensen M. Relationship of hiatus hernia to reflux oesophagitis. A prospective study of coincidence, using endoscopy. Scand J Gastroenterol 1986;21:55-8.
4. Howard PJ, Maher L, Pryde A, Heading RC. Symptomatic gastro-oesophageal reflux, abnormal oesophageal acid exposure, and mucosal acid sensitivity are three separate, though related, aspects of gastro-oesophageal reflux disease. Gut 1991;32:128-32.
5. Ben Rejeb M, Bouché O, Zeitoun P. Study of 47 consecutive patients with peptic esophageal stricture compared with 3880 cases of reflux esophagitis. Dig Dis Sci 1992;37:733-6.
6. Wienbeck M, Li Q. Cisapride in gastro-oesophageal reflux disease: effects on oesophageal motility and intra-oesophageal pH. Scand J Gastroenterol 1989;24 Suppl 165:13-8.
7. Baldi F, Ferrarini F, Longanesi A, Angeloni M, Ragazzini M, Barbara L. Effect of short-term cisapride treatment on gastrooesophageal reflux disease. Prog Med 1987;43 Suppl 1:29-34.
8. Collins BJ, Spence RAJ, Ferguson R, Laird J, Love AHG. Cisapride: influence on oesophageal and gastric emptying and gastro-oesophageal reflux in patients with reflux oesophagitis. Hepatogastroenterol 1987;34:113-6.
9. Lepoutre L, Vanderlinden I, Bollen G, Vandewalle N, Cabooter M, Laukens P. Controlled study of cisapride in the treatment of grade II and III oesophagitis. Gastroenterology 1987;92:1501 A.
10. Baldi F, Bianchi Porro G, Dobrilla G, Iascone C, Lobello R, Marzio L, et al. Cisapride versus placebo in reflux esophagitis. J Clin Gastroenterol 1988;10:614-8.
11. Dodds W, Champion M, Orr W, Robinson M, Spechler S, Gilmore P, et al. Oral cisapride in GERD: a double-blind placebo-controlled multicenter trial. Gastroenterology 1989;96: A126.
12. Toussaint J, Gossuin A, Deruyttere M, Hublé F, Devis G. Healing and prevention of relapse of reflux oesophagitis by cisapride. Gut 1991;32:1280-5.
13. DeMicco M, Berenson M, Wu W, Castell D, Lanza F, Robinson M, et al. Cisapride in the treatment of GERD: a double-blind, placebo-controlled multicenter dose-response trial. Gastroenterology 1992;102:A59.
14. Faruqui S, Sigmund C, Smith R, Fitch D, Mellow M, Orr W, et al. Cisapride in the treatment of GERD: a double-blind, placebo-controlled multicenter dose-response trial. Gastroenterology 1992;102:A66.
15. Blum AL, Adami B, Bouzo MH, Brandstätter G, Fumagalli I, Galmiche JP, et al. Effect of cisapride on relapse of esophagitis. A multinational, placebo-controlled trial in patients healed with an antisecretory drug. Dig Dis Sci 1993;38:551-60.
16. Tytgat GNJ, Anker Hansen OJ, Carling L, de Groot GH, Geldof H, Glise H, et al. Effect of cisapride on relapse of reflux oesophagitis, healed with an antisecretory drug. Scand J Gastroenterol 1992;27:175-83.
17. de Boer WA, Tytgat GNJ. Review article: drug therapy for reflux oesophagitis. Aliment Pharmacol Ther 1994;8:147-57.
18. Savary M, Miller G L'oesophage. Manuel et atlas d'endoscopie. Soleure, Suisse: Verlag Gassmann AG; 1977.
19. Report of a working party. World Congress of Gastroenterology; 1988 Rome.
20. Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, et al. A comparison of five maintenance therapies for reflux esophagilis. N Engl J Med 1995;333:1106-10.
21. Tytgat GNJ, Blum AL, Verlinden M. Prognostic factors for relapse and maintenance treatment with cisapride in gastrooesophageal reflux disease. Aliment Pharmacol Ther 1995;9:271-80.
22. Waldum HL, Amestad JS, Brenna E, Eide I, Syversen U, Sandvik AK. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gastroenterology 1996:110:A289.
23. Prewett EJ, Hudson M, Nwokolo CU, Sawyerr AM, Pounder RE. Nocturnal intragastric acidity during and after a period of dosing with either ranitidine or omeprazole. Gastroenterology 1991;100:873-7.
24. Kimmig JM. Treatment and prevention of relapse of mild oesophagitis with omeprazole and cisapride: comparison of two strategies. Aliment Pharmacol Ther 1995;9:281-6.